DataCanvas completes an extended Series D round, while Healsun Biopharm completes an extended Series B round.
DataCanvas seals $41m Series D1 round
DataCanvas, which develops and operates an automated data science platform designed for data scientists, has secured 300 million yuan ($41.1 million) in a Series D1 round, the Beijing-headquartered firm announced on Sunday.
The round saw the participation of state-owned investors including Taiping Innovation Capital, the private equity arm of China Taiping Insurance Group; a fund under China Electronics Corporation; Orient Jiafu Asset Management; and People’s Capital, among others.
Venture capital firm Z&Y Capital also joined the round, per the announcement.
Founded in 2013, the firm previously raised an extended Series C in September 2022, without divulging the financial details. Dragon Gate Investment Partners led the round, while Delta Capital and Lingfeng Capital were among some of the participating investors.
Healsun Biopharm bags $27.4m in Series B+ round
Healsun Biopharm, which serves as a domestic contract development and manufacturing organisation (CDMO), has raised 200 million yuan ($27.4 million) in a Series B+ round.
Hong Kong-listed pharmaceutical and medical products maker China Medical System Holdings led the latest financing round, while existing shareholder Orient Jiafu Asset Management re-upped, according to a company announcement.
The proceeds will be used to ramp up hires as well as for overseas business expansion, among others.
Founded in 2015, the Hangzhou-headquartered firm secured nearly 250 million yuan ($36.7 million) in a Series B round of financing led by the 10-billion-yuan ($1.5 billion) Shanghai Biomedical Industry Equity Investment Fund in August 2022.
The firm offers services ranging from early drugability evaluation, culture medium customisation, and process development for biopharmaceutical drugs including antibody-drug conjugates, to pilot production, IND application, and clinical sample production.